IDH1-mutated relapsed or refractory AML: current challenges and future prospects by Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P

Get full text

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review by Cortes, JE, Candoni, A, Clark, RE, Leber, B, Montesinos, P, Vyas, P, Zeidan, AM, Heuser, M

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum] by Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyagüez I, Brockbank J, Iglesias T, Llinares J, Sierra J

Get full text

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain by Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyagüez I, Brockbank J, Iglesias T, Llinares J, Sierra J

Get full text

Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the ra... by DiNardo, CD, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Zeidan, AM, Bluemmert, I, Yu, X, Hasan, M, Martin-Regueira, P, de Botton, S

Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (A... by DiNardo, CD, Dohner, H, Zeidan, AM, Schuh, AC, Vyas, P, Stein, EM, Wei, AH, de Botton, S, Chen, C, Lord-Bessen, J, Martin-Regueira, P, Lersch, F, Gong, J, Guo, S, Shi, L, Montesinos, P

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, p... by DiNardo, CD, Schuh, AC, Stein, EM, Montesinos, P, Wei, AH, de Botton, S, Zeidan, AM, Fathi, AT, Kantarjian, HM, Bennett, JM, Frattini, MG, Martin-Regueira, P, Lersch, F, Gong, J, Hasan, M, Vyas, P, Döhner, H

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemi... by Dinardo, CD, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Zeidan, AM, Chen, C, Lord-Bessen, J, Yu, P, Shi, L, Guo, S, Bluemmert, I, Yu, X, Hasan, M, Martin Regueira, P, De Botton, S

A phase 3 study of Enasidenib (ENA) versus conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 (MIDH2) relapsed/refractory acute myeloid leukemia (R/R AM... by Papayannidis, C, DiNardo, C, Montesinos, P, Schuh, A, Vyas, P, Wei, A, Ommen, H, Semochkin, S, Kim, H, Larson, R, Koprivnikar, J, Frankfurt, O, Thol, F, Chromik, J, Byrne, J, Pigneux, A, Thomas, X, Salamero, O, Vidriales, M, Doronin, V, Dohner, H, Fathi, A, Laille, E, Yu, X, Hasan, M, Martin-Regueira, P, de Botton, S

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial by de Botton, S, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Ommen, H, Semochkin, S, Kim, H-J, Larson, RA, Koprivnikar, J, Frankfurt, O, Thol, F, Chromik, J, Byrne, J, Pigneux, A, Thomas, X, Salamero, O, Vidriales, MB, Doronin, V, Döhner, H, Fathi, AT, Laille, E, Yu, X, Hasan, M, Martin-Regueira, P, DiNardo, CD

AML-262 Pivekimab Sunirine (PVEK, IMGN632) triplet with azacitidine and venetoclax shows broad activity in adverse genetic subsets of relapsed/refractory acute myeloid leukemia and... by Daver, N, Montesinos, P, Aribi, A, Martinelli, G, Altman, JK, Wang, ES, Roboz, GJ, Burke, PW, Gaidano, G, Walter, RB, Thomas, X, Jeyakumar, D, DeAngelo, DJ, Erba, HP, Todisco, E, Begna, K, Advani, A, Gastaud, L, de la Fuente, A, Curti, A, Mendez, LM, Vyas, P, Boissel, N, Vey, N, Recher, C, Longval, T, Platzbecker, U, Kapp-Schwörer, S, Schliemann, C, Konopleva, M, Torres, L, Sallman, DA, Marcucci, G, Marconi, G, Kantarjian, H, Sloss, CM, Malcolm, KE, Zweidler-McKay, PA, Sweet, K

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts by Zeidan, AM, Boddu, PC, Patnaik, MM, Bewersdorf, JP, Stahl, M, Rampal, RK, Shallis, R, Steensma, DP, Savona, MR, Sekeres, MA, Roboz, GJ, DeAngelo, DJ, Schuh, AC, Padron, E, Zeidner, JF, Walter, RB, Onida, F, Fathi, A, DeZern, A, Hobbs, G, Stein, EM, Vyas, P, Wei, AH, Bowen, DT, Montesinos, P, Griffiths, EA, Verma, AK, Keyzner, A, Bar-Natan, M, Navada, SC, Kremyanskaya, M, Goldberg, AD, Al-Kali, A, Heaney, ML, Nazha, A, Salman, H, Luger, S, Pratz, KW, Konig, H, Komrokji, R, Deininger, M, Cirici, BX, Bhatt, VR, Silverman, LR, Erba, HP, Fenaux, P, Platzbecker, U, Santini, V, Wang, ES, Tallman, MS